SEATTLE–Rosetta Biosoftware today announced that Stanford University has licensed the Syllego™ system for the management and analysis of genetic data produced by the GENEticS of Insulin Sensitivity (GENESIS) consortium. GENESIS researchers in the Quertermous lab at Stanford University will use the Syllego system to support genome-wide association studies (GWAS) targeted at the genetic mechanisms underlying insulin sensitivity.

To date, diabetes-related GWAS have revealed genes associated with insulin production and have not focused on sensitivity to insulin in peripheral tissues. Insulin sensitivity is believed to be largely determined at the genetic level. The GENESIS consortium studies will consist of cohorts of thousands of patients in whom insulin action is measured as a primary phenotype.

“The Syllego system will provide a benefit to our investigation of the genetic basis of insulin sensitivity, by aiding in our interpretation of whole genome-wide scan data,” said Thomas Quertermous, Director, Division of Cardiovascular Medicine (Research), Stanford Cardiovascular Medicine. “Not only does it enable us to manage and access data generated by GENESIS consortium members and therefore promote collaboration, the Syllego system will also provide us with critical information we need to design our follow-up mapping studies in replication cohorts as well as our laboratory-based mechanistic studies in animal models.”

Designed for integrative genomics studies, the Syllego system provides comprehensive support for managing and analyzing genome-wide association, copy number variation, linkage and eQTL data. As a collaborative platform, it enables biologists, statistical geneticists, principal investigators and other research team members to access and interpret these data within a single interface.

About the Syllego System

The Syllego system is Rosetta Biosoftware’s practical solution for genetic data management and analysis. The Syllego system includes the Affymetrix GeneChip®-compatible designation and is part of the Illumina® Connect program. For more information on the Syllego system, please visit www.rosettabio.com/syllego.

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver, Rosetta Elucidator, and Rosetta Syllego systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly-owned subsidiary of Merck & Co., Inc. More information about Rosetta Biosoftware is available at www.rosettabio.com.

Forward-Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics’ technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics’ technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2008, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver, Resolver, Elucidator, and Syllego are trademarks of Rosetta Inpharmatics LLC.